scholarly journals 1031-134 Relationship between the transcardiac increase of plasma heart-type fatty acid-binding protein and left ventricular remodeling in patients with dilated cardiomyopathy

2004 ◽  
Vol 43 (5) ◽  
pp. A164 ◽  
Author(s):  
Keijin Ohno ◽  
Takayoshi Tsutamoto ◽  
Chitose Ishikawa ◽  
Hiroshi Sakai ◽  
Takashi Tsutsui ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Dilated Cardiomyopathy ◽  
Fatty Acid Binding Protein ◽  
Ventricular Remodeling ◽  
Left Ventricular Remodeling ◽  
Binding Protein ◽  
Left Ventricular ◽  
Fatty Acid Binding ◽  
Acid Binding Protein

scholarly journals Role of the fatty acid-binding protein 4 in heart failure and cardiovascular disease

2017 ◽  
Vol 233 (3) ◽  
pp. R173-R184 ◽  
Author(s):  
Ricardo Rodríguez-Calvo ◽  
Josefa Girona ◽  
Josep M Alegret ◽  
Alba Bosquet ◽  
Daiana Ibarretxe ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cardiovascular Disease ◽  
Fatty Acid ◽  
Fatty Acid Binding Protein ◽  
Binding Protein ◽  
Left Ventricular ◽  
Aetiological Factor ◽  
Fatty Acid Binding ◽  
Acid Binding Protein

Obesity and ectopic fat accumulation in non-adipose tissues are major contributors to heart failure (HF) and cardiovascular disease (CVD). Adipocytes act as endocrine organs by releasing a large number of bioactive molecules into the bloodstream, which participate in a communication network between white adipose tissue and other organs, including the heart. Among these molecules, fatty acid-binding protein 4 (FABP4) has recently been shown to increase cardiometabolic risk. Both clinical and experimental evidence have identified FABP4 as a relevant player in atherosclerosis and coronary artery disease, and it has been directly related to cardiac alterations such as left ventricular hypertrophy (LVH) and both systolic and diastolic cardiac dysfunction. The available interventional studies preclude the establishment of a direct causal role of this molecule in CVD and HF and propose FABP4 as a biomarker rather than as an aetiological factor. However, several experimental reports have suggested that FABP4 may act as a direct contributor to cardiac metabolism and physiopathology, and the pharmacological targeting of FABP4 may restore some of the metabolic alterations that are conducive to CVD and HF. Here, we review the current knowledge regarding FABP4 in the context of HF and CVD as well as the molecular basis by which this protein participates in the regulation of cardiac function.

Circulating adipocyte fatty acid-binding protein levels are independently associated with heart failure

2012 ◽  
Vol 124 (2) ◽  
pp. 115-122 ◽  
Author(s):  
Mingya Liu ◽  
Mi Zhou ◽  
Yuqian Bao ◽  
Zhiyong Xu ◽  
Huating Li ◽  
...  
Keyword(s):  
Heart Failure ◽  
Fatty Acid ◽  
Fatty Acid Binding Protein ◽  
Binding Protein ◽  
Multivariate Logistic Regression Analysis ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Fatty Acid Binding ◽  
Ventricular Ejection Fraction ◽  
Acid Binding Protein

A-FABP (adipocyte fatty acid-binding protein), one of the most abundant proteins in adipocytes, plays a key role in obesity-related insulin resistance, inflammation and atherosclerosis in animals. In the present study, we sought to investigate the association of A-FABP with HF (heart failure) in Chinese subjects. Serum A-FABP levels were measured in 252 HF patients and 261 age-, gender- and BMI (body mass index)-matched non-HF subjects. Echocardiography was performed on each patient. The severity of HF was determined by the NYHA (New York Heart Association) classification system. After adjustments for age, gender and BMI, serum A-FABP concentrations in patients with HF were significantly higher than in non-HF patients [11.17 (6.63–19.93) ng/ml compared with 5.67 (3.20–8.87) ng/ml; P<0.001] and significantly progressed with the NYHA class (P<0.001). In addition, NT-proBNP (N-terminal pro-brain natriuretic peptide) was independently and positively correlated with A-FABP (standardized β=0.340, P<0.001) after adjusting for confounding factors. Each echocardiographic parameter, especially LVEF (left ventricular ejection fraction), was independently associated with A-FABP (all P<0.05). Multivariate logistic regression analysis demonstrated that A-FABP concentration was an independent risk factor for HF [odds ratio, 6.93 (95% confidence interval, 2.49–19.30); P<0.001]. Our results demonstrate that A-FABP is closely associated with HF, and raise the possibility that increased A-FABP may be causally related to the pathogenesis of heart dysfunction in humans.

Fatty acid binding protein 4 predicts left ventricular mass and longitudinal function in overweight and obese women

Heart ◽  
2013 ◽  
Vol 99 (13) ◽  
pp. 944-948 ◽  
Author(s):  
Stefan Engeli ◽  
Wolfgang Utz ◽  
Sven Haufe ◽  
Valéria Lamounier-Zepter ◽  
Martin Pofahl ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Left Ventricular Mass ◽  
Fatty Acid Binding Protein ◽  
Binding Protein ◽  
Left Ventricular ◽  
Obese Women ◽  
Fatty Acid Binding ◽  
Acid Binding Protein ◽  
Longitudinal Function ◽  
Ventricular Mass

Abstract 389: Elevation of Fatty Acid-Binding Protein 4 is Associated with Left Ventricular Hypertrophy and Diastolic Dysfunction in a General Population

Hypertension ◽  
2013 ◽  
Vol 62 (suppl_1) ◽  
Author(s):  
Tomohiro Mita ◽  
Masato Furuhashi ◽  
Satoshi Yuda ◽  
Atsuko Muranaka ◽  
Shutaro Ishimura ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Blood Pressure ◽  
Fatty Acid ◽  
General Population ◽  
Diastolic Dysfunction ◽  
Fatty Acid Binding Protein ◽  
Binding Protein ◽  
Left Ventricular ◽  
Fatty Acid Binding ◽  
Acid Binding Protein

Fatty acid-binding protein 4 (FABP4/A-FABP/aP2) is expressed in both adipocytes and macrophages. Recent studies have shown secretion of FABP4 from adipocytes and association of elevated serum FABP4 level with obesity, insulin resistance, hypertension, and atherosclerosis. However, little is known about role of FABP4 in cardiac function. From database of the Tanno-Sobetsu Study, a study with prospective population-based cohort design, all data from female subjects who were on no medication and underwent echocardiography in 2011 (n = 108) were retrieved for analyses of relationships between serum FABP4 concentration, metabolic markers and parameters of echocardiography. FABP4 level was positively correlated with age, body mass index (BMI), blood pressure, triglycerides, HOMA-R, left ventricular (LV) wall thickness (LVWT; r = 0.39, p < 0.01), and E/e’ (r = 0.32, p < 0.01), an index of impaired LV relaxation, and negatively correlated with the ratio of early diastolic to atrial systolic velocity (E/A) of transmitral flow (r = -0.30, p < 0.01). FABP4 concentration was not significantly correlated with LV ejection fraction or LV diastole diameter. Multiple regression analysis adjusted by age and blood pressure revealed that FABP4 concentration was independently correlated with LVWT and E/e’. However, FABP4 level was not selected as an independent determinant of LVWT or E/e’ when BMI and/or HOMA-R were additionally incorporated into the adjustment. In conclusion, FABP4 may contribute to LV hypertrophy and diastolic dysfunction via facilitation of obesity and insulin resistance in the general population.

Sign in / Sign up

Export Citation Format

Share Document